What are the Historical Developments and Current Growth Metrics of the Weight Loss Drugs Market?
The weight loss drugs market has seen considerable growth due to a variety of factors.
• The market size of weight loss medications has expanded dramatically in the past few years. It is projected to rise from $2.87 billion in 2024 to hit $4.23 billion in 2025, with a compound annual growth rate (CAGR) of 47.6%.
This historical growth can be credited to escalating obesity levels, shifts in lifestyle, rising awareness and education, early identification of health conditions, along with an increase in healthcare spending.
What Does Future Hold for The Weight Loss Drugs Market By 2029?
The weight loss drugs market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the size of the weight loss drugs market, which is set to experience significant growth in the upcoming years. By 2029, predictions have it growing to a total of $17.08 billion with a compound annual growth rate (CAGR) of 41.7%.
The projected growth during this period can be attributed to several factors, including an aging population, the impact of social media, evolving fitness and wellness trends, societal standards of beauty, and investments in the pharmaceutical industry. During the forecasted period, the market is expected to be shaped by numerous trends such as technological enhancement, a shift towards non-prescription solutions, the rise of personalized medicine and combination therapies, product innovation, and enhanced post-market surveillance.
What Are The Primary Growth Drivers In The Weight Loss Drugs Market?
The escalating prevalence of obesity is anticipated to stimulate the expansion of the weight loss drugs market. The term "obesity rate" pertains to the percentage of persons in a specific demographic who possess a body mass index (BMI) of 30 or above. Medications utilized in the treatment of obesity, often known as weight loss drugs, aid individuals in losing weight by suppressing appetite, enhancing satiety, or disrupting nutrient absorption. For example, as per the data from a US-based governmental institution, the Centers for Disease Control and Prevention, the prevalence of adult obesity surpassed 35% in 19 states in 2021 and 22 states in 2022 as of September 2023. Furthermore, the prevalence of adult obesity was at or exceeded 35% in 2022. Moreover, in March 2023, according to the World Obesity Federation, a non-profit organization based in the UK, over 4 billion individuals are projected to be obese by 2035. Consequently, the surge in obesity rates is accelerating the growth of the weight loss drugs market.
What Is The Segmentation Of The Global Weight Loss Drugs Market?
The weight loss drugs market covered in this report is segmented –
1) By Type: Liquid, Tablets, Capsules
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Weight-Reducing Aid, Fat Absorption Inhibitors, Metabolic Boosters
Subsegments:
1) By Liquid: Syrups, Solutions, Suspensions
2) By Tablets: Immediate-Release Tablets, Extended-Release Tablets
3) By Capsules: Hard Capsules, Softgel Capsules
Pre-Book The Weight Loss Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Weight Loss Drugs Market?
Leading organizations in the weight loss drug market are inventing groundbreaking products like Zepbound (tirzepatide) injection to effectively attend to patients. Zepbound is a once-a-week injectable agent that stimulates dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. For instance, in November 2023, Eli Lilly and Company, a pharmaceutical firm based in the US, received FDA endorsement for tirzepatide injection (Zepbound) for chronic weight control in adults with excess weight or obesity and at least one weight-related condition. Zepbound boasts the potential to be a commercially viable drug since it is the only FDA-approved obesity treatment that triggers both GIP and GLP-1 receptors.
Who Are the Key Players In The Weight Loss Drugs Market?
Major companies operating in the weight loss drugs market report are:
• Pfizer Inc.
• Roche
• Merck & Co.
• AbbVie Inc.
• Novartis AG
• Bristol Myers Squibb
• Sanofi S.A.
• AstraZeneca PLC
• LG Chem
• GlaxoSmithKline
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• Bayer AG
• Amgen Inc.
• Boehringer Ingelheim group
• Novo Nordisk A/S
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Hisun Pharmaceutical
• Taj Pharmaceuticals Ltd.
• Zhongshan Pharmaceutical Co. Ltd.
• Dm Pharma
• Lunan Pharmaceutical Group Corporation
• Wolfson Berg Ltd.
• Swiss Research Labs Ltd.
What Are The Regional Insights Into The Weight Loss Drugs Market?
North America was the largest region in the Weight Loss Drugs market in 2024. The regions covered in the weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
